Atrial fibrillation Atrial fibrillation
Conditions
Interventions
None listed
Sponsors
Okamatsu Hideharu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with atrial fibrillation and a serum creatinine level of 1.5 mg/dL or higher who are undergoing their first catheter ablation for atrial fibrillation using the PulseSelect system
Exclusion criteria
Exclusion criteria: Patients currently participating in other clinical trials or clinical studies (interventional studies) Left ventricular ejection fraction of 35% or less Left atrial diameter of 55 mm or more Long-standing atrial fibrillation lasting 3 years or longer Serum creatinine < 1.5 mg/dL Patients undergoing maintenance dialysis Post-valvular surgery (including catheter-based procedures) Post-Maze surgery Severe valvular disease Active malignancy Patients who have undergone pulsed-field ablation for indications other than pulmonary vein isolation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Degree of increase in free hemoglobin in T2, T3, and T4 Degree of increase in creatinine in T2, T3, and T4 Incidence of kidney disease at Stage 1 or higher according to the KDIGO clinical guidelines | — |
Secondary
| Measure | Time frame |
|---|---|
| The extent of elevation in total bilirubin and LDH in T2, T3, and T4 The extent of decrease in serum hemoglobin in T2,T3, and T4 The extent of elevation in BUN in T2, T3, and T4 The frequency of patients whose haptoglobin levels fell below the detection limit on the day after surgery | — |
Contacts
Public ContactHideharu Okamatsu
Saiseikai Kumamoto Hospital
Outcome results
None listed